Journal article icon

Journal article

Rituximab capping triggers intracellular reorganisation of B cells

Abstract:

The antibody rituximab, which binds to the protein CD20 on the surface of B-cells, has been used to treat B-cell malignancies for several years. However, the molecular mechanisms underlying this treatment are not yet fully understood. One well-established rituximab-induced mechanism, natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC), has recently been described to involve the polarisation of bound rituximab and CD20 to one side of the B-cell. B-cells polarised ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.19185/matters.201612000001

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
RDM - Investigative Medicine Division
Role:
Author
Expand authors...
Wolfson Foundation More from this funder
Expand funders...
Publisher:
Science Matters Publisher's website
Journal:
Matters Journal website
Publication date:
2017-01-01
Acceptance date:
2016-12-29
DOI:
ISSN:
2297-8240
Source identifiers:
694071
Keywords:
Pubs id:
pubs:694071
UUID:
uuid:3d20ab44-e5ca-4b02-b9af-7a52a232c100
Local pid:
pubs:694071
Deposit date:
2017-05-11

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP